Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
JANKU, FILIP
One or more keywords matched the following items that are connected to JANKU, FILIP
Item TypeName
Concept Sirolimus
Academic Article Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.
Academic Article Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer.
Academic Article A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma.
Academic Article Ridaforolimus in advanced sarcomas: a leap forward or missed opportunity?
Academic Article A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies.
Academic Article Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.
Academic Article Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.
Academic Article Epithelial to mesenchymal transition is associated with rapamycin resistance.
Academic Article Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.
Academic Article Epithelial to mesenchymal transition is associated with rapamycin resistance
Academic Article Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
Academic Article Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.
Academic Article Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.
Academic Article Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.
Academic Article Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients.
Concept Mechanistic Target of Rapamycin Complex 1
Academic Article Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies.
Academic Article Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma.
Academic Article Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
Search Criteria
  • Sirolimus